Zrinka Planinić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zrinka Planinić has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Jozica Šikić
University of Zagreb, School of Medicine, Zagreb, Croatia
26 shared publications - Ante Pašalić
Klinička bolnica "Sveti Duh", Zagreb, Hrvatska
13 shared publications - Edvard Galić
Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia
13 shared publications - Marko Perčić
University of Rijeka, Centre for Micro- and Nanosciences and Technologies Centre for Artificial Intelligence and Cybersecurity,Faculty of Engineering,Rijeka,Croatia
13 shared publications - Tea Friščić
Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia
13 shared publications - Jasna Čerkez Habek
Clinical Hospital Sveti Duh Zagreb Croatia
9 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Critical Care
- Vol. 2026 (1) , 9589641
Extracorporeal Cooling in Heat Stroke Induced Takotsubo Cardiomyopathy
Heat stroke is a life‐threatening condition characterized by elevated core body temperature (≥ 40°C) and central nervous system (CNS) dysfunction, resulting from body′s inability to adequately dissipate heat. It can lead to multiorgan failure, including the cardiovascular system. Takotsubo cardiomyopathy (TCM), also known as stress‐induced cardiomyopathy, is an acute syndrome of transient global or regional ventricular dysfunction, most commonly apical ballooning, mimicking acute coronary syndrome, typically occurring after severe physical or emotional stress. Although individually well‐described, the combination of severe heat stroke as a trigger for TCM is rare. This case report describes a female patient with severe heat stroke who developed TCM and, due to persistent hyperthermia unresponsive to conventional cooling methods, was successfully cooled using prolonged intermittent hemodiafiltration. It also highlights the importance of timely recognition of atypical complications such as TCM in patients with cardiovascular instability and demonstrates the potential role of hemodialysis as an effective cooling method in cases of refractory hyperthermia.
- 1 January 2026
- Published by Wiley in Case Reports in Critical Care
- Vol. 2026 (1) , 9589641
Open AccessExtracorporeal Cooling in Heat Stroke Induced Takotsubo Cardiomyopathy
Heat stroke is a life‐threatening condition characterized by elevated core body temperature (≥ 40°C) and central nervous system (CNS) dysfunction, resulting from body′s inability to adequately dissipate heat. It can lead to multiorgan failure, including the cardiovascular system. Takotsubo cardiomyopathy (TCM), also known as stress‐induced cardiomyopathy, is an acute syndrome of transient global or regional ventricular dysfunction, most commonly apical ballooning, mimicking acute coronary syndrome, typically occurring after severe physical or emotional stress. Although individually well‐described, the combination of severe heat stroke as a trigger for TCM is rare. This case report describes a female patient with severe heat stroke who developed TCM and, due to persistent hyperthermia unresponsive to conventional cooling methods, was successfully cooled using prolonged intermittent hemodiafiltration. It also highlights the importance of timely recognition of atypical complications such as TCM in patients with cardiovascular instability and demonstrates the potential role of hemodialysis as an effective cooling method in cases of refractory hyperthermia.
- Open Access
- 10 December 2025
- Published by Wiley
Hormonal multireceptor agonism for treatment of metabolic and non-metabolic conditions - potential value of glucagon receptor agonism
A successful translation of glucagon-like peptide 1 (GLP-1) physiology into multiple pharmaceutical solutions has greatly improved our ability to treat conditions like Type 2 diabetes mellitus (T2DM), obesity, and obesity-associated comorbidities, and to prevent poor long-term health outcomes. This success has triggered increased interest in exploiting gut and pancreatic hormone physiology for the development of improved therapeutics. To build on the success of GLP-1 receptor mono-agonists, many research groups have focused on developing multi-receptor agonists with improved efficacy profiles. A dual gastrointestinal inhibitory peptide (GIP) receptor/GLP-1 receptor agonist, tirzepatide, has already shown benefits in the treatment of T2DM and obesity compared to GLP-1 receptor mono-agonists. Multiple other development programs are investigating the value of combining glucagon (GCG) receptor agonism with GLP-1 receptor agonism. The rationale is based on the physiological role of GCG in energy metabolism, including appetite suppression and, presumably, increased energy expenditure. These mechanisms are considered to enhance the effect of mono-agonism on adipose tissue mass in people with obesity. More recently, new data regarding the physiological roles of GCG beyond energy metabolism have emerged, potentially broadening the opportunities for utilizing its physiology in drug development strategies. In this review, we summarise findings from ongoing clinical development programs investigating drugs that activate the GCG receptor in combination with other entero-pancreatic hormone pathways. As several of these programs approach potential marketing authorisation, it is essential for the scientific and clinical communities to remain informed about new evidence and to prepare for the integration of these therapies into clinical practice.
- 10 December 2025
- Published by Wiley
Open AccessHormonal multireceptor agonism for treatment of metabolic and non-metabolic conditions - potential value of glucagon receptor agonism
A successful translation of glucagon-like peptide 1 (GLP-1) physiology into multiple pharmaceutical solutions has greatly improved our ability to treat conditions like Type 2 diabetes mellitus (T2DM), obesity, and obesity-associated comorbidities, and to prevent poor long-term health outcomes. This success has triggered increased interest in exploiting gut and pancreatic hormone physiology for the development of improved therapeutics. To build on the success of GLP-1 receptor mono-agonists, many research groups have focused on developing multi-receptor agonists with improved efficacy profiles. A dual gastrointestinal inhibitory peptide (GIP) receptor/GLP-1 receptor agonist, tirzepatide, has already shown benefits in the treatment of T2DM and obesity compared to GLP-1 receptor mono-agonists. Multiple other development programs are investigating the value of combining glucagon (GCG) receptor agonism with GLP-1 receptor agonism. The rationale is based on the physiological role of GCG in energy metabolism, including appetite suppression and, presumably, increased energy expenditure. These mechanisms are considered to enhance the effect of mono-agonism on adipose tissue mass in people with obesity. More recently, new data regarding the physiological roles of GCG beyond energy metabolism have emerged, potentially broadening the opportunities for utilizing its physiology in drug development strategies. In this review, we summarise findings from ongoing clinical development programs investigating drugs that activate the GCG receptor in combination with other entero-pancreatic hormone pathways. As several of these programs approach potential marketing authorisation, it is essential for the scientific and clinical communities to remain informed about new evidence and to prepare for the integration of these therapies into clinical practice.
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 198
A heart on the edge: aortic dilatation, severe combined aortic and mitral regurgitation with reduced ejection fraction dilated cardiomyopathy
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 198
A heart on the edge: aortic dilatation, severe combined aortic and mitral regurgitation with reduced ejection fraction dilated cardiomyopathy
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 189
Severe aortic stenosis in a patient with transthyretin cardiac amyloidosis
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 189
Severe aortic stenosis in a patient with transthyretin cardiac amyloidosis
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 202
Complete heart block as a manifestation of combined mitral valve and aortic root infective endocarditis
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 202
Complete heart block as a manifestation of combined mitral valve and aortic root infective endocarditis
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 184
CROVALV 2025
- 1 September 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (7-8) , 184
CROVALV 2025
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 257
Retrospective analysis of patients with severe valvular heart disease requiring treatment at University Hospital “Sveti Duh” in a two-year period
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 257
Retrospective analysis of patients with severe valvular heart disease requiring treatment at University Hospital “Sveti Duh” in a two-year period
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 249
How to deal with calcified mitral stenosis and diastolic dysfunction
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 249
How to deal with calcified mitral stenosis and diastolic dysfunction
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 259
Mitral valve prolapse and sudden cardiac death
- 1 August 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (9-10) , 259
Mitral valve prolapse and sudden cardiac death